Your session is about to expire
← Back to Search
APG-2575 + Azacitidine for Acute Myeloid Leukemia
Study Summary
This trial is testing a new combination of drugs to treat leukemia and related diseases.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have an active infection or hepatitis B/C, HIV, and am vaccinated against COVID-19.I have a specific type of leukemia (APL or AML/MPAL with BCR-ABL1 positive).I cannot swallow pills or have serious digestive issues.My cervical or breast cancer was treated while it was still in the early stage.I have recovered from previous cancer treatments, except for hair loss.I do not have any severe illnesses that would stop me from following the study's requirements.I am currently experiencing or being treated for graft-versus-host disease.I had cancer before, treated with the goal of curing it, and need to discuss this.I have not taken strong CYP3A4 inhibitors or inducers in the last week.I agree to use birth control during the study.I have received leukemia treatment within the last 14 days.I have leukemia in my brain that is not under control.I have a type of skin cancer that is either basal cell or squamous cell.My leukemia involves more than one type of blood cell.My leukemia has returned or didn't respond to treatment, and standard therapies are not expected to work.My MDS did not improve after 4 cycles of HMA therapy or it got worse after initially responding to HMA.I've had a stem cell transplant within the last 6 months.I haven't had any other cancers in the last 2 years, except for certain types.You are allergic to any of the ingredients in the treatment program.I may need hydroxyurea for my fast-growing cancer until 24 hours before and during the first treatment cycle.The doctor thinks that you have a condition or situation that would not be suitable for this study.
- Group 1: APG2575 + Azacitidine
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What type of patients does APG 2575 ramp up arm typically help?
"APG 2575 ramp up arm is most often used to target malignant neoplasms. However, this same treatment can be applied to other conditions such as 20-30% blasts, neutropenia and/or thrombocytopenia, and anemia."
Is it possible for me to sign up and participate in this research project?
"This ongoing clinical trial is seeking 24 leukemia patients that are aged 18 to 99. Furthermore, these individuals must have a histologically confirmed relapsed or refractory diagnosis of acute myeloid leukemia, mixed phenotype acute leukemia, Chronic Myelomonocytic Leukemia, or Higher-Risk MDS. Lastly, eligible patients should not have received standard therapies nor be expected to respond well to them."
Do we have a wide geographic sample for this clinical trial?
"7 sites are running this trial. They are: MDACC in Houston, Swedish Medical Center in Seattle, MD Anderson in Charlotte, as well other locations."
Is this the first time APG 2575 has been used in a clinical setting?
"APG 2575 was first used in a 2006 study at Chinese University of Hong Kong-Prince of Wales Hospital. To date, there have been 160 completed trials with APG 2575. At the moment, 179 studies are actively recruiting patients; many of these taking place in Houston, Texas."
How many test subjects are included in this experiment?
"That is accurate, the clinical trial mentioned is currently open and looking for patients. According to the listing on clinicaltrials.gov, the trial was first posted on 7/30/2021 and edited most recently on 11/10/2022. They are hoping to find 24 participants total from 7 different locations."
Does this treatment regimen exclude elderly patients?
"To qualify for this clinical trial, applicants must between 18-99 years old. There are 466 other trials available for patients who are underaged and 1382 additional options for seniors."
Share this study with friends
Copy Link
Messenger